Apogee Therapeutics Inc. (APGE)
NASDAQ: APGE
· Real-Time Price · USD
37.36
-0.76 (-1.99%)
At close: Aug 15, 2025, 3:59 PM
36.48
-2.36%
After-hours: Aug 15, 2025, 07:58 PM EDT
Apogee Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | 130K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 400K | 207K | n/a | 48K | 36K | 29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -400K | -207K | 65K | -48K | -36K | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -73.17M | -63.1M | -75.88M | -58.69M | -44.12M | -38.18M | -37.16M | -24.3M | -18.89M | -12.66M | -14.1M | -10.51M | -1.82M | -4.3M |
Interest Income | 7.14M | 7.84M | 8.68M | 9.67M | 10.31M | 6.09M | 5.42M | 3.46M | n/a | 133K | 92K | n/a | n/a | n/a |
Pretax Income | -72K | -55.26M | -67.2M | -49.02M | -33.82M | -32.09M | -31.73M | -20.84M | -18.89M | -12.53M | -14.01M | -19.66M | -1.82M | -4.3M |
Net Income | n/a | -55.34M | -67.22M | -49.02M | -33.82M | -32.09M | -31.73M | -20.84M | -18.89M | -12.53M | -14.01M | -19.66M | -1.82M | -4.3M |
Selling & General & Admin | 17.46M | 16.71M | 15.65M | 12.97M | 10.92M | 9.44M | 8.2M | 7.24M | 4.94M | 4.2M | 1.89M | 622K | 368K | 60K |
Research & Development | 55.7M | 46.39M | 60.23M | 45.71M | 33.21M | 28.72M | 28.95M | 17.07M | 13.95M | 8.46M | 12.21M | 9.88M | 1.45M | 4.25M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 73.17M | 63.1M | 75.88M | 58.69M | 44.12M | 38.15M | 37.16M | 24.3M | 18.89M | 12.66M | 14.1M | 10.51M | 1.82M | 4.3M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 9.15M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 73.17M | 63.1M | 75.88M | 58.69M | 44.12M | 38.18M | 37.16M | 24.3M | 18.89M | 12.66M | 14.1M | 10.51M | 1.82M | 4.3M |
Income Tax Expense | -72K | -83K | 18K | n/a | n/a | -14.28K | -37.16K | n/a | -18.89K | -12.66K | 37.12K | -10.51K | n/a | n/a |
Shares Outstanding (Basic) | 58.43M | 58.2M | 55.19M | 56.8M | 56.52M | 50.19M | 50.66M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M |
Shares Outstanding (Diluted) | 58.43M | 58.2M | 55.19M | 56.8M | 56.52M | 50.19M | 50.66M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M |
EPS (Basic) | -1.13 | -0.95 | -1.22 | -0.86 | -0.6 | -0.64 | -0.63 | -0.41 | -0.37 | -0.25 | -0.28 | -0.39 | -0.04 | -0.09 |
EPS (Diluted) | -1.13 | -0.95 | -1.22 | -0.86 | -0.6 | -0.64 | -0.63 | -0.41 | -0.37 | -0.25 | -0.28 | -0.39 | -0.04 | -0.09 |
EBITDA | -73.17M | -63.1M | -75.81M | -58.64M | -44.09M | -38.15M | -31.73M | -20.84M | -18.89M | n/a | n/a | n/a | n/a | n/a |
EBIT | -66.02M | -55.26M | -75.88M | -58.69M | -44.12M | -38.18M | -31.73M | -20.84M | -18.89M | -12.66M | -14.01M | -10.51M | -1.82M | -4.3M |
Depreciation & Amortization | n/a | 207K | 76K | 48K | 36K | 29K | n/a | n/a | 18.89M | 12.66M | 16.89M | 10.51M | 1.82M | 4.3M |